{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T05:29:30Z","timestamp":1648963770205},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.eimc.2018.09.013","type":"journal-article","created":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T00:12:39Z","timestamp":1543018359000},"page":"367-372","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of mono\/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV\/HCV-coinfected patients"],"prefix":"10.1016","volume":"37","author":[{"given":"Luz","family":"Mart\u00edn-Carbonero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Dom\u00ednguez-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Bail\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Ron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikel","family":"Rico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Jimenez-Nacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luisa","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2018.09.013_bib0115","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2016 Sep 12."},{"key":"10.1016\/j.eimc.2018.09.013_bib0120","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/QAD.0000000000001465","article-title":"Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV","volume":"31","author":"Montes","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2018.09.013_bib0125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/cid\/ciw379","article-title":"All-oral Direct-acting Antiviral Regimens in HIV\/Hepatitis C Virus\u2013coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13\u2013HEPAVIH Cohort","volume":"63","author":"Sogni","year":"2016","journal-title":"Clin Infect Dis."},{"issue":"36 Suppl","key":"10.1016\/j.eimc.2018.09.013_bib0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/liv.13021","article-title":"HCV-HIV co-infected patients: no longer a \u201cspecial\u201d population?","volume":"1","author":"Sulkowski","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.eimc.2018.09.013_bib0135","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimc.2018.09.013_bib0140","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial","volume":"313","author":"Sulkowski","year":"2015","journal-title":"JAMA."},{"key":"10.1016\/j.eimc.2018.09.013_bib0145","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"The Lancet HIV."},{"key":"10.1016\/j.eimc.2018.09.013_bib0150","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimc.2018.09.013_bib0155","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2893.2009.01180.x","article-title":"Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV\/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers","volume":"17","author":"S\u00e1nchez-Conde","year":"2010","journal-title":"J Viral Hepat."},{"key":"10.1016\/j.eimc.2018.09.013_bib0160","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/hiv.12348","article-title":"Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials","volume":"17","author":"Arribas","year":"2016","journal-title":"HIV Med."},{"key":"10.1016\/j.eimc.2018.09.013_bib0165","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkw379","volume":"72","author":"Perez-Molina","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.eimc.2018.09.013_bib0170","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. 2018 Jan 12;:1-6."},{"key":"10.1016\/j.eimc.2018.09.013_bib0175","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw059","article-title":"Human Immunodeficiency Virus\/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics","volume":"3","author":"Berenguer","year":"2016","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.eimc.2018.09.013_bib0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/QAI.0b013e31815ac47d","article-title":"Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV\/hepatitis C virus coinfection","volume":"47","author":"Opravil","year":"2008","journal-title":"J Acquir Immune Defic Syndr."},{"key":"10.1016\/j.eimc.2018.09.013_bib0185","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx158","article-title":"Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus\/Human Immunodeficiency Virus Coinfection","volume":"4","author":"Boesecke","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.eimc.2018.09.013_bib0190","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.29814","article-title":"All oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human inmmunodeficiency virus\/HCV coinfected subjects in real world practice: Madrid coinfection registry finding","volume":"68","author":"Berenguer","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2018.09.013_bib0195","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jhep.2011.01.051","article-title":"Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study","volume":"55","author":"Robic","year":"2011","journal-title":"J Hepatol. Elsevier;"},{"key":"10.1016\/j.eimc.2018.09.013_bib0200","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.21665","article-title":"Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis","volume":"45","author":"Vizzutti","year":"2007","journal-title":"Hepatology."},{"key":"10.1016\/j.eimc.2018.09.013_bib0205","doi-asserted-by":"crossref","first-page":"e95776","DOI":"10.1371\/journal.pone.0095776","article-title":"Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease","volume":"9","author":"Pang","year":"2014","journal-title":"PLoS ONE."},{"key":"10.1016\/j.eimc.2018.09.013_bib0210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/hep.25616","article-title":"Liver stiffness predicts clinical outcome in human immunodeficiency virus\/hepatitis C virus-coinfected patients with compensated liver cirrhosis","volume":"56","author":"Merchante","year":"2012","journal-title":"Hepatology."},{"key":"10.1016\/j.eimc.2018.09.013_bib0215","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/QAD.0b013e3283573267","article-title":"Transient elastography to rule out esophageal varices and portal hypertensive gastropathy in HIV-infected individuals with liver cirrhosis","volume":"26","author":"Montes Ramirez","year":"2012","journal-title":"AIDS."},{"key":"10.1016\/j.eimc.2018.09.013_bib0220","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut."}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X18302775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X18302775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:59:07Z","timestamp":1559051947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X18302775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0213005X18302775"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2018.09.013","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of mono\/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV\/HCV-coinfected patients","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2018.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}